Meet DGD Pharma’s Scientific Advisors

team

Wayne Klohs, PhD

Dr. Klohs has over thirty-five years of experience in the pharmaceutical industry with increasing levels of responsibility held in positions across the drug development and discovery spectrum. He currently consults for numerous biotech and pharma companies focused in oncology after retiring from Astellas Pharma Inc. as a Senior Vice President and Global Therapeutic Head for Oncology.
team

Theodore S. Lawrence, MD, PhD, FASTRO, FASCO

Dr. Lawrence is the Isadore Lampe Professor and Chair of the Department of Radiation Oncology. He is a member of the Association of American Physicians (AAP) and the National Academy of Medicine (NAM). Dr. Lawrence joined the faculty of the University of Michigan in 1987, following a fellowship in medical oncology and a residency in radiation oncology at the National Cancer Institute. He received his research degree in cell biology from the Rockefeller University, followed by his medical degree from Cornell University and an internal medicine residency at Stanford University.

Dr. Lawrence is an editor of the Cancer Journal, the associate editor of Seminars in Radiation Oncology, a senior editor for Cancer Research, and a scientific editor for Cancer Discovery. He has been President of the American Society of Radiation Oncology (ASTRO), The Radiation Oncology Institute (ROI), and of the Society of Chairs of Radiation Oncology Programs (SCAROP), Chair of the National Cancer Institute’s Board of Scientific Councilors, the founding Chair of the Radiation Sciences and Medicine Working Group of the American Association of Cancer Research (AACR), a member of the NCI Board of Scientific Advisors, and a member of the Board of Directors of the American Society of Clinical Oncology (ASCO).

Dr. Lawrence’s interests in the laboratory are focused on molecularly targeted and immunotherapeutic radiosensitizers. His clinical research combines these laboratory studies with conformal radiation guided by advanced imaging and blood biomarkers for the treatment of patients with gastrointestinal and central nervous system malignancies. He is the author of over 300 peer-reviewed publications, and his work has been continuously supported by the National Cancer Institute for over 25 years. For his accomplishments, he has been awarded the Gold Medal of ASTRO and of the Israeli Society of Clinical Oncology, which are the highest awards conferred by those societies, an ASCO Statesman Award, and the Radiological Society of North America’s (RSNA) Outstanding Researcher Award.

Read More
team

Mukesh Nyati, PhD

Professor Nyati has been focused on basic, translational as well as clinical aspects related to EGFR signaling over the last 20 years. Dr. Nyati is working at the Department of Radiation Oncology of the University of Michigan on developing novel therapeutic agents to selectively inhibit active EGFR dimer formation to induce tumor-specific degradation of EGFR. He is a co-founder of DGD Pharmaceuticals, Corp, and its acting Chief Scientific Officer. Dr Nyati received his Ph.D. from the University of Rajasthan, Jaipur, India and post-doctoral training at the Indian Institute of Science, Bangalore, India and at the University of Michigan, Ann Arbor, MI.